Seventeen patients with pancreatic carcinoma and 30 patients with gastric carcinoma were treated with diaziquone on days 1 and 8 of repeated 4-week courses. No objective responses were seen. Toxicity was primarily myelosuppression, nausea, and vomiting. Since only 10 chemotherapy-naive patients were treated in each disease category, we do not regard this as a definitive trial, but our experience suggests that this dose schedule is not likely to be useful in these types of cancer.